Table 4.
Studies describing HPV and high-risk type-specific prevalence from different countries
| Country | Study design | Test method | HPV prevalence | Comment | Cervical cancer incidence rate per 100 000 [17]a |
|---|---|---|---|---|---|
| Denmark Kjær SK, 2008 [20] |
Population-based and opportunistic screening N = 11617 aged 15-93 years |
Hybrid capture 2 testing | Any - 26.4% High risk - 23% |
HPV peak prevalence at the age 20-24 (50.2%) Most prevalent high risk HPV 16 (6.0% of all women) |
12.6 |
| United Kingdom Sargent A, 2008 [23] |
Routine screening program, N = 24510 aged 20-64 years |
Hybrid capture 2 testing | High risk All ages - 10.6% 20-29 y - 27.3% 30-39 y - 10.3% 40-49 y - 4.2% 50-64 y - 2.5% |
Most prevalent high risk HPV 16, 18, 31, 51, 52 | 8.3 |
| Finland Leinonen M, 2008 [19] |
Population based screening, N = 16895 aged 25-65 years |
Hybrid capture 2 testing | High risk - 7.5% | High risk HPV peak prevalence at the age 25-29 (24.1%) | 4.3 |
| Netherlands Coupe VMH, 2008 [22] |
RC population based screening trial N = 45362 Aged 18-65 |
GP5+/6+-PCR EIA | High risk - 5.6% | High risk peak prevalence at the age 18-24 (21.2%) Most prevalent high risk HPV 16, 31,18 |
7.3 |
| Norway Skjeldestad FE 2008 [21] |
N = 898 Aged 16-24 (healthy, non-pregnant, sexually experienced) |
PCR | HPV 6,11,16,18 - 26% HPV 16, 18 - 20.8% HPV 6, 11 - 9.6% |
HPV 16 prevalence 16.3% HPV 18 prevalence 7.3% |
10.4 |
| USA Dunne EF, 2007 [4] |
Probability sampling, nationally representative sample (NHANES 2003-4) N = 1921 Aged 14-59 |
PCR | Any - 26.8% High risk - 15.2% Low risk - 17.8% |
HPV peak prevalence at the age 20 to 24 (44.8%) Most prevalent high risk HPV 53, 52, 59 Most prevalent low risk HPV 62, 84, 89 |
7.7 |
| Latvia Silins I, 2004 [35] |
Healthy controls from population registry N = 239 aged 18-89 (cervical cancer risk factor study) |
PCR | High risk - 8% (HPV 16 and 18 only) | 12.9 | |
| Russia Aleksandrova YN, 2000 [36] |
Attendants of gynecological clinics N = 309 reproductive age; lacking the clinical or morphological symptoms of HPV-related diseases |
PCR | Any - 29% | HPV were overrepresented among women reporting excessive number of contraceptive abortions |
11.9 |
| Three NIS of former Soviet Union Kulmala SM, 2007 [30] |
Consecutive out-patient clinic attendees N = 3187 (STI clinics n = 722, gynecological patients n = 761, cervical cancer screening n = 1,692) |
Hybrid capture 2 testing | High risk - 31.2% * STI clinic - 40.8%, * gynecological patients - 30.9%, * screening - 27.2% |
Most prevalent high risk HPV 16, 31, 33 | NA |
| Russia Kulmala SM, 2007 [30] |
Consecutive out-patient clinic attendees N = 1967 |
Hybrid capture 2 testing | High risk - 33.4%, | Most prevalent high risk HPV 16, 31,33 | 11.9 |
| Belarus Kulmala SM, 2007 [30] |
Consecutive out-patient clinic attendees N = 568 |
Hybrid capture 2 testing | High risk - 27.5%, | Most prevalent high risk HPV 16, 33, 31 | 13.1 |
| Latvia Kulmala SM, 2007 [30] |
Consecutive out-patient clinic attendees N = 442 |
Hybrid capture 2 testing | High risk - 26.2% | Most prevalent high risk HPV 16, 33, 39 | 12.9 |
a Age-standardized rate